首页 › 多发性骨髓瘤 › 俄亥俄州 › Cleveland
Cleveland OH 多发性骨髓瘤临床试验
14项针对 多发性骨髓瘤的研究正在 Cleveland及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
招募中3 期
- Cleveland Clinic, Cleveland
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
招募中2 期
- Cleveland Clinic, Cleveland
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
招募中3 期
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Main Campus, Cleveland
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Cleveland Clinic, Cleveland
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
招募中观察性研究
- University Hospitals Seidman Cancer Center, Cleveland
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
招募中3 期
- Cleveland Clinic, Cleveland
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
招募中1 期
- Cleveland Clinic - Taussig Cancer Institute, Cleveland
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
招募中3 期
- Research Site, Cleveland
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
招募中3 期
- Research Site, Cleveland
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
招募中2 期
- University Hospitals Cleveland Medical Center, Cleveland
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
招募中3 期
- MetroHealth Medical Center, Cleveland
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
招募中3 期
- Research Site, Cleveland
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
招募中1 期
- Cleveland Clinic, Cleveland
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
招募中1/2 期
- University Hospitals Cleveland, Cleveland
其他城市的 多发性骨髓瘤试验
- New York City, NY59 项研究
- Boston, MA45 项研究
- Atlanta, GA42 项研究
- Houston, TX39 项研究
- Durham, NC36 项研究
- Nashville, TN31 项研究
- Denver, CO26 项研究
- St. Louis, MO26 项研究
- Rochester, MN25 项研究
- Columbus, OH25 项研究
- Chicago, IL24 项研究
- Milwaukee, WI23 项研究
Cleveland的其他研究
- 非小细胞肺癌48 项研究
- 癌症（所有类型）36 项研究
- 乳腺癌33 项研究
- 心力衰竭31 项研究
- 转移性癌症30 项研究
- 前列腺癌30 项研究
- 卵巢癌29 项研究
- 肺癌26 项研究
- 结直肠癌25 项研究
- 急性髓系白血病20 项研究
- 头颈鳞状细胞癌20 项研究
- 心血管疾病20 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。